IN2014DN08495A - - Google Patents
Info
- Publication number
- IN2014DN08495A IN2014DN08495A IN8495DEN2014A IN2014DN08495A IN 2014DN08495 A IN2014DN08495 A IN 2014DN08495A IN 8495DEN2014 A IN8495DEN2014 A IN 8495DEN2014A IN 2014DN08495 A IN2014DN08495 A IN 2014DN08495A
- Authority
- IN
- India
- Prior art keywords
- treatment
- atypical antipsychotic
- disorders amenable
- amenable
- disorders
- Prior art date
Links
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 | |
| PCT/US2013/031413 WO2013138602A1 (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08495A true IN2014DN08495A (enExample) | 2015-05-08 |
Family
ID=48407766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8495DEN2014 IN2014DN08495A (enExample) | 2012-03-14 | 2013-03-14 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (enExample) |
| EP (2) | EP2825167B1 (enExample) |
| JP (5) | JP2015510893A (enExample) |
| KR (2) | KR20140121487A (enExample) |
| CN (2) | CN108938632A (enExample) |
| AU (2) | AU2013232014B2 (enExample) |
| BR (1) | BR112014022687A8 (enExample) |
| CA (1) | CA2865845C (enExample) |
| CL (1) | CL2014002430A1 (enExample) |
| CO (1) | CO7091183A2 (enExample) |
| ES (2) | ES2677474T3 (enExample) |
| IL (1) | IL234412B (enExample) |
| IN (1) | IN2014DN08495A (enExample) |
| MX (1) | MX374067B (enExample) |
| RU (1) | RU2651710C2 (enExample) |
| WO (1) | WO2013138602A1 (enExample) |
| ZA (1) | ZA201406369B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| ES2870498T3 (es) | 2015-02-17 | 2021-10-27 | Vanda Pharmaceuticals Inc | Iloperidona para el tratamiento de esquizofrenia |
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| AU2023408198A1 (en) * | 2022-12-19 | 2025-05-29 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
| IL324466A (en) * | 2023-06-02 | 2026-01-01 | Vanda Pharmaceuticals Inc | Method of treatment with iloperidone |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| JP2005504783A (ja) | 2001-08-31 | 2005-02-17 | ノバルティス アクチエンゲゼルシャフト | イロペリドン代謝産物の光学異性体 |
| DE60239634D1 (de) | 2001-12-10 | 2011-05-12 | Novartis Ag | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| WO2006039663A2 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals, Inc | Methods for the administration of iloperidone |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| WO2008121899A2 (en) | 2007-03-29 | 2008-10-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| JP5535914B2 (ja) | 2007-09-10 | 2014-07-02 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｓｎｐ遺伝子型に基づく抗精神病薬治療 |
| CA2698534C (en) | 2007-09-10 | 2018-10-09 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
| US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| WO2010117931A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
| US9074256B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| JP5881597B2 (ja) | 2009-04-06 | 2016-03-09 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｑｔ延長に対する素因を予測する方法 |
| ES2533091T3 (es) | 2009-05-15 | 2015-04-07 | Vanda Pharmaceuticals Inc. | Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1 |
-
2013
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 MX MX2014010989A patent/MX374067B/es active IP Right Grant
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en not_active Ceased
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko not_active Ceased
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko not_active Ceased
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY4167Q (es) | Par de auriculares | |
| TWD174059S (zh) | 速克達摩托車 | |
| TWD167893S (zh) | 戒指 | |
| TWD165137S (zh) | 錶 | |
| EP3038647A4 (en) | Combination therapy for the treatment of glioblastoma | |
| TWD158887S (zh) | 粉餅盒 | |
| EP3041578A4 (en) | Treatment of inflammatory diseases by carbon materials | |
| TWD171869S (zh) | 速克達摩托車 | |
| TWD166111S (zh) | 速克達摩托車 | |
| PH12017500747A1 (en) | Heterocyclic compound | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| IN2013DE00266A (enExample) | ||
| CR20140528A (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1 | |
| EP3009515A4 (en) | Production of microbial oils | |
| IN2014DN08495A (enExample) | ||
| AU352731S (en) | Safety apparatus | |
| TWD163566S (zh) | 心電圖監視器 | |
| UY34843A (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| IN2013MU01113A (enExample) | ||
| BR112015024771A2 (pt) | cateter | |
| MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| BR112015022412A2 (pt) | bucha elétrica | |
| AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
| SMT201700072B (it) | Utilizzo del pidotimod per il trattamento della psoriasi | |
| IN2014DN07191A (enExample) |